SCHEMBL13041639

SCHEMBL13041639

CC(C)CN1Cc2ccccc2N(C(C)C)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.43
▸ OPRM1 P35372 3/20 0.36
▸ OPRL1 P41146 2/20 0.36
▸ DPP4 P27487 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CYP2D6 P10635 2/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ BRS3 P32247 1/20 0.34
▸ SLC22A1 O15245 1/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ ADRA2A P08913 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ DRD1 P21728 1/20 0.33
▸ TBXA2R P21731 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041625 0.85 ALDH1A1 (0.39) PARP1OPRM1OPRL1DPP4SMN1; SMN2
SCHEMBL13041630 0.84 ALDH1A1 (0.43) PARP1OPRM1OPRL1DPP4SMN1; SMN2
SCHEMBL13041631 0.82 ENPP2 (0.51) PARP1OPRM1OPRL1SMN1; SMN2L3MBTL1
SCHEMBL13041641 0.81 BRD4 (0.41) PARP1OPRM1OPRL1DPP4SMN1; SMN2
SCHEMBL13041635 0.80 PARP1 (0.43) PARP1SMN1; SMN2HSD17B10TDP1CYP2D6
SCHEMBL13041634 0.80 PARP1 (0.43) PARP1HSD17B10L3MBTL1BRS3CHRM2
SCHEMBL13041643 0.80 ALOX15 (0.36) OPRM1OPRL1DPP4SMN1; SMN2CYP2D6
SCHEMBL13041644 0.78 OPRL1 (0.42) OPRM1OPRL1DPP4OPRK1
SCHEMBL13015326 0.78 BRD4 (0.42) PARP1OPRM1OPRL1DPP4SMN1; SMN2
SCHEMBL26661186 0.78 SMN1; SMN2 (0.39) DPP4SMN1; SMN2TSHRL3MBTL1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100278835-A1 NOVEL COMPOUNDS 660 ASTRAZENECA UK LIMITED (GB) 2010-11-04 — — US disclosed
US-20100278835-A1 NOVEL COMPOUNDS 660 ASTRAZENECA UK LIMITED (GB) 2010-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100278835-A1 NOVEL COMPOUNDS 660 RB1, RPP30, SARS1 PARP1 3310/4885OPRM1 1102/4885OPRL1 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback